Jade Therapeutics

Recently acquired by Eyegate Pharma, Jade Therapeutics is focused on developing locally administered, polymer-based products designed to treat poorly-served ophthalmic indications. Jade’s proprietary, cross-linked, bio-erodible hydrogel technology has demonstrated a variety of unique and beneficial characteristics, whether employed alone or as a sustained-release drug-delivery vehicle. This approach could enable improved therapeutic outcomes along with increased patient compliance to therapy, decreased frequency of administration and office visits, and avoidance of subsequent surgeries – ultimately resulting in better visual outcomes with enhanced quality of life. The company has six programs under development for diverse ocular indications.